Physician

Babak Jian Seyedahmadi, M.D.

According to 2025 Medicare claims, Babak Seyedahmadi, M.D. (NPI: 1538262761) practices ophthalmology in the Boston, MA market, with the plurality of this provider's patient population coming from Plymouth, MA. This provider's primary affiliated billing organization is OPHTHALMIC CONSULTANTS OF BOSTON, INC. (NPI: 1437374428; TIN: 04-2500346) and primary practice location at 02189-3110. Seyedahmadi is affiliated with the Mass General Brigham ACO, LLC (ACO ID: A4641), participating under the MSSP model.

Seyedahmadi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 2,546 traditional Medicare patients, billed 69,151 HCPCS/CPT codes, and received $7,823,248 in Medicare payments. The top billing code was Q5124 (Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg). Part D data shows 635 prescription claims across 196 beneficiaries totaling $21,701 in drug costs, led by Prednisolone Acetate (Prednisolone Acetate). No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,446,494 to $7,823,248. Concurrently, Part D prescription costs have changed little. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$3.9M$7.8M2015 Medicare payment: $2,446,494 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $2,959,097 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $2,645,321 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $3,090,038 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $3,508,306 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $3,298,543 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $3,427,923 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $3,358,659 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $4,459,564 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $7,823,248 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20151,87413,891$2,446,494
20162,07717,065$2,959,097
20172,08915,779$2,645,321
20182,04618,887$3,090,038
20192,11122,255$3,508,306
20201,95321,457$3,298,543
20212,04723,802$3,427,923
20222,23227,477$3,358,659
20232,26335,533$4,459,564
20242,54669,151$7,823,248

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$12K$25K2015 Drug cost: $19,768 (USD; Tot_Drug_Cst)2016 Drug cost: $23,426 (USD; Tot_Drug_Cst)2017 Drug cost: $24,567 (USD; Tot_Drug_Cst)2018 Drug cost: $24,481 (USD; Tot_Drug_Cst)2019 Drug cost: $19,363 (USD; Tot_Drug_Cst)2020 Drug cost: $15,858 (USD; Tot_Drug_Cst)2021 Drug cost: $22,558 (USD; Tot_Drug_Cst)2022 Drug cost: $18,831 (USD; Tot_Drug_Cst)2023 Drug cost: $22,821 (USD; Tot_Drug_Cst)2024 Drug cost: $21,701 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015110342$19,768
2016158550$23,426
2017155538$24,567
2018184530$24,481
2019169528$19,363
2020134409$15,858
2021159552$22,558
2022188661$18,831
2023189668$22,821
2024196635$21,701

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
Q5124Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg43918,905$134
92014Established patient complete exam of visual system2,2422,948$93
67028Injection of drug into eye7916,298$93
92012Established patient problem focused exam of visual system7441,084$72
92134Imaging of retina2,3297,136$32

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Prednisolone AcetatePrednisolone Acetate1694,196$4,925
Atropine SulfateAtropine Sulfate731,367$1,651
LatanoprostLatanoprost1004,804$1,057
OfloxacinOfloxacin911,872$894
Ketorolac TromethamineKetorolac Tromethamine21527$419

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

FAQ

What Medicare data is available for Babak Jian Seyedahmadi, M.D.?

Tedicare shows public-source Medicare data for Babak Jian Seyedahmadi, M.D. (NPI 1538262761), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Babak Jian Seyedahmadi, M.D. have ACO affiliation data?

Babak Jian Seyedahmadi, M.D. is shown with ACO affiliation data for Mass General Brigham ACO, LLC (MSSP, ACO ID A4641).

What billing organization is linked to Babak Jian Seyedahmadi, M.D.?

Babak Jian Seyedahmadi, M.D. is linked to OPHTHALMIC CONSULTANTS OF BOSTON, INC. (billing NPI 1437374428) in the available physician profile data.

Does Babak Jian Seyedahmadi, M.D. have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.